X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BPZE1 is a next-generation live-attenuated pertussis vaccine designed to induce comprehensive and durable protection against B. pertussis infection (colonization) and disease (whooping cough).
Lead Product(s): BPZE1
Therapeutic Area: Infections and Infectious Diseases Product Name: BPZE1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
BPZE1 is the most advanced next generation pertussis vaccine, designed to overcome deficiencies of current vaccines, including limited durability and the inability to prevent nasopharyngeal Bordetella pertussis infections that lead to transmission.
Lead Product(s): Live-attenuated Bordetella Pertussis Vaccine,Azithromycin,Bordetella Pertussis Challenge Strain
Therapeutic Area: Infections and Infectious Diseases Product Name: BPZE1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Knott Partners
Deal Size: $42.8 million Upfront Cash: Undisclosed
Deal Type: Series D Financing September 06, 2022
Details:
BPZE1 is only next generation live-attenuated intranasal pertussis vaccine in clinical trials designed to protect against Bordetella pertussis nasal infection and active disease through induction of broad and sustained mucosal and systemic immunity.
Lead Product(s): BPZE1
Therapeutic Area: Infections and Infectious Diseases Product Name: BPZE1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Details:
In addition to preclinical development of B-Tech Vector vaccines for TB and other targets, ILiAD continues to advance its BPZE1 pertussis vaccine through late-stage clinical development.
Lead Product(s): Tuberculosis Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Funding April 26, 2022
Details:
Fast Track Designation for BPZE1 is based on the positive topline results from Phase 2b trial demonstrating that BPZE1 induced durable mucosal immunity and reduced nasal colonization and, it has the potential to address unmet medical needs for such a disease or condition.
Lead Product(s): BPZE1
Therapeutic Area: Infections and Infectious Diseases Product Name: BPZE1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2022
Details:
BPZE1 is a live attenuated vaccine and next generation pertussis vaccine in advanced clinical trials which is designed to protect against Bordetella pertussis nasal infection and developed as a booster vaccine with future development investigating its application in infants.
Lead Product(s): BPZE1
Therapeutic Area: Infections and Infectious Diseases Product Name: BPZE1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2021
Details:
Poster titled "Assessment Of Safety And Immunologic Responses Of BPZE1, An Intranasal Live Attenuated Pertussis Vaccine, In Healthy Adults" wil be presested at the conference.
Lead Product(s): BPZE1
Therapeutic Area: Infections and Infectious Diseases Product Name: BPZE1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
BPZE1 prevented colonization from re-vaccination/challenge in 90% of subjects with no vaccine related serious adverse events.
Lead Product(s): BPZE1
Therapeutic Area: Infections and Infectious Diseases Product Name: BPZE1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
ILiAD Biotechnologies will be presenting new data from its Phase 2b clinical trial of lead pertussis vaccine candidate, BPZE1, at the World Vaccine Congress to be held virtually.
Lead Product(s): BPZE1
Therapeutic Area: Infections and Infectious Diseases Product Name: BPZE1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
